SML1586

Oritavancin diphosphate

98.0% ~ 102.0% (HPLC)

• Synonym(e): LY333328 diphosphate, (4"R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-α-L-arabino-hexopyranosyl)-N3"-[(4′-chloro[l,1′-biphenyl]-4-yl)methyl]vancomycin diphosphate, LY-333328
• Empirische Formel (Hill-System): C₈₆H₉₇Cl₃N₁₀O₂₆ · 2H₃PO₄
• CAS-Nummer: 192564-14-0
• Molekulargewicht: 1989.09
• UNSPSC Code: 12352200
• NACRES: NA.77
• Assay: 98-102% (HPLC)
• Form: powder

Eigenschaften

• Produktname: Oritavancin diphosphate, 98-102% (HPLC)
• Quality Segment: 100
• assay: 98-102% (HPLC)
• form: powder
• color: white to off-white
• storage temp.: 2-8°C
• SMILES string: [P](=O)(O)(O)O.[P](=O)(O)(O)O.Clc1ccc(cc1)c2ccc(cc2)CN[C@@]3([C@H]([C@@H](O[C@H](C3)O[C@H]4[C@@H](O[C@@H]([C@H]([C@@H]4O)O)CO)Oc5c6cc7cc5Oc8c(cc(cc8)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]7C(=O)N[C@@H]9c%10cc(c(cc%10)O)c%11c(cc(cc%11O)O)[C@H](NC(=O)[C@@H](NC9
• InChI: 1S/C86H97Cl3N10O26.2H3O4P/c1-35(2)22-51(92-7)77(110)98-67-69(105)42-15-20-55(49(88)24-42)120-57-26-44-27-58(73(57)125-84-74(71(107)70(106)59(34-100)122-84)124-62-32-86(6,76(109)37(4)119-62)93-33-38-8-10-39(11-9-38)40-12-17-45(87)18-13-40)121-56-21-16-43(25-50(56)89)72(123-61-31-85(5,91)75(108)36(3)118-61)68-82(115)97-66(83(116)117)48-28-46(101)29-54(103)63(48)47-23-41(14-19-53(47)102)64(79(112)99-68)96-80(113)65(44)95-78(111)52(30-60(90)104)94-81(67)114;2*1-5(2,3)4/h8-21,23-29,35-37,51-52,59,61-62,64-72,74-76,84,92-93,100-103,105-109H,22,30-34,91H2,1-7H3,(H2,90,104)(H,94,114)(H,95,111)(H,96,113)(H,97,115)(H,98,110)(H,99,112)(H,116,117);2*(H3,1,2,3,4)/t36-,37-,51+,52-,59+,61-,62-,64+,65+,66-,67+,68-,69+,70+,71-,72+,74+,75-,76-,84-,85-,86-;;/m0../s1
• InChI key: PWTROOMOPLCZHB-BHYQHFGMSA-N

Beschreibung

Biochem/physiol Actions

Oritavancin is a lipoglycopeptide vancomycin analog with broad spectrum activity against gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and organisms resistant to vancomycin and other antibiotics such as linezolid and daptomycin. Oritavancin has multiple mechanisms of action, including inhibition of transglycosylation, inhibition of transpeptidation, and cell membrane interaction/disruption. Oritavancin also has a long half-life, allowing for a single intravenous dose of rather than the standard vacomycin treatment of twice-daily infusions for ten days.

Oritavancin is a lipoglycopeptide vancomycin analog with broad spectrum activity against gram-positive pathogens.

Disclaimer

category 1 skin sensitizer

Sicherheitshinweise

• Piktogramme: GHS07
• Signalwort: Warning
• Gefahrencodes: H317
• Sicherheitshinweise: P261 - P272 - P280 - P302 + P352 - P333 + P313 - P362 + P364
• Hazard Classifications: Skin Sens. 1A
• Lagerklasse: 11 - Combustible Solids
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable